partnering between business, universities and the nhs · 2018-02-07 · conclusions on partnering...

Partnering between Business, Universities and the NHS

7:45am : 18 June 2013 Nicholas.Edwards@ouh.nhs.uk

www.OxfordAHSN.org

Chris Goard Nick Edwards Jon Rees

Your Panel …

Agenda • The Opportunity for UK Life Sciences

• AHSN Concept

• Oxford Region

• Oxford AHSN

The UK opportunity: better exploitation of scientific strength

“The UK is the most productive leading economic nation in research, delivering more highly cited publications both per £ spent, and per

researcher, than any of the other leading scientific nations.”

UK Life Science Strategy: Dec 2011 “In December 2011 I made a firm commitment to re-establish the UK‘s global leadership in the life science sector, announcing the Government’s ten-year Strategy for UK Life Sciences. By more closely integrating the UK's unique strengths, I believe that we can improve healthcare for patients, attract new investment to the UK, and create new jobs and business opportunities in an increasingly competitive and international industry.”

David Cameron Prime Minister

The Strategy makes the most of the UK’s core strengths: Basic science in universities Translational and clinical research Industry The National Health Service (NHS)

Partnering: Crossing the valley

Agenda • The Opportunity for UK Life Sciences

• AHSN Concept

• Oxford Region

• Oxford AHSN

Academic Health Science Networks

• 15 English Regions

• Co-terminus with NIHR Clinical Research

• Nested AHSCs

Thanks to East Midlands AHSN

Classes of medical innovation • Pharmaceuticals : Small, Biological & Vaccines • Medical Diagnostics and Devices • ATMP (Advanced Therapy Medicinal Products)

Gene Therapies, Cell Therapies and Tissue Engineering • Information Technology / Mobile Health • Clinical Decision Making and Practice • Surgical Innovations • Healthcare Delivery & Management • Health Promotion / Disease Prevention

Two types of innovation 1. Inherently novel advances

2. Increasing availability and uptake to drive

best care by making best use of existing tools, products or services

Innovation and “best practice” How consistently do we deliver “Best Care”? 1.Atlas of Variation (www.rightcare.nhs.uk) 2.Protocol/Pathway compliance 3.Variability in drug use 4.Doctor preference 5.Clinical outcomes and audit

AHSN core purpose • Ensuring and supporting the adoption and spread of innovations

for rapid diffusion • Leading local work in the NHS on innovation and its role in

supporting the delivery of high quality cost-effective health care - enabling partners in the AHSN to help each other to improve - adoption and implementation of innovation and best practice

• Supporting knowledge exchange networks to provide for rapid evaluation and early adoption of innovations

• Delivering research together • Supporting industry research • Pump priming innovation projects • Running Small Business Research Initiative (SBRI) and similar

competitions for innovations from industry • Raise the standards and quality of NHS services • Providing advice on intellectual property management to NHS and

universities • Identifying and supporting the development, testing and

commercialisation of ideas • Work with procurement teams to support systematic adoption and

spread

NHS, Universities and Businesses …

… working better together for mutual benefit.

Ready, willing and able to partner?

• Bringing products to market • Deploying capital

Ready, willing and able to partner?

Roles and Benefits

• Basic science • Training decision makers

• Managing knowledge

• Research projects/impact

• Teaching and careers

• Creation/piloting/trials • Adoption and sales

• Trialing products • Buying products

• Care quality • Innovation &

improvement

Ready, willing and able to partner?

Ready ? Is there a need to partner or just an opportunity ?

Willing ? Is there a willingness to adapt and adopt new behaviours ?

Able ? Are mechanisms in place to make it happen ?

Ready, willing and able?

Business Universities NHS

Ready ? Need innovation and route to market

Need to show “impact”

Need to adopt and use innovation to deliver best care

Willing ? Open Innovation and Partnering

Co-located joint “Institutes”

Joint Working, Open Data

Able ? ? ? ?

How will an AHSN help? • Intelligence & Information sharing • Identifying needs and opportunities • Introducing individuals • Inspiring ideas and innovators • Initiating new businesses • Instigating collaborations • Independent influence • Influencing national priorities To …. Improve Patient Care Increase Wealth Intensify Research Impact

How can business benefit ? • Identifying customer needs and

opportunities • Ideas for new products / services • Early & quick assessments by

potential customers • Evaluating / Piloting / Trials • Adoption and Dissemination To …. Improve Patient Care Increase Wealth Intensify Research Impact

Agenda • The Opportunity for UK Life Sciences

• AHSN Concept

• Oxford Region

• Oxford AHSN

Times Higher Education Top 50

Oxford research income for clinical medicine

Oxford : Medical Research & “Translation” • Biomedical Research

Centre • Institute of

Biomedical Engineering

• Biobank • Jenner Institute • Weatherall Institute

• Ludwig • CTSU • CEBM • HEXI / HeLEX / Ethox • OCGF • Glycobiology Institute • Etc. etc.

Oxford Medical Research

ORC: Old Road Campus JR: John Radcliffe CH: Churchill NOC: Nuffield Orthopaedic Centre WF: Warneford

• Welcome Trust Centre for Human genetics

• Kennedy Institute for Rheumatology

• Structural Genomics Consortium

• Target Discovery Institute • Big Data Institute • BioEscalator / Incubator (in

development)

Innovation = Open Innovation

• Remove fences around R&D facilities • Break down internal silos preventing open

sharing of ideas • Re-think IP policies and the relationship

between your IP and the “Commons”

Structural Genomics Consortium • Not-for-profit, public-

private partnership determining 3D protein structures relevant to drug discovery

• Pre-competitive IP free, “Open Access” model

• Consortium involving Pfizer, Novartis, Eli Lilly, GSK, Abbott, Takeda, and two others ($8m each)

• Reinventing drug discovery www.thesgc.org

BIG data Prime Minister joins Sir Ka-shing Li for launch of £90m

initiative in big data and drug discovery at Oxford on 3 May

2013 “Big data to revolutionise healthcare” “Radical boost for drug discovery” PM: 'What’s happening today really matters ... I think it’s going to lead to huge breakthroughs …’

Oxford University spin-outs 2000 7

Third Phase, Mindweavers, Oxford BioSignals, Oxford BioSensors, TolerRx, OXIVA, Pharma DM

2001 7OxLoc, Oxford Bee Co, Oxford Ancestors, Novarc, Oxford ArchDigital, Natural Motion, Inhibox

2002 9Pharminox, Minervation, Oxford Biomaterials(Spinox), Zyentia, Oxitec, Oxford Immunotec, Oxford Risk, GlycoForm, BioAnalab

2003 4 Summit(Vastox)*, ReOx, Riotech, OCSI

2004 4 Avacta(OMD)*, G-Nostics, Surface Therapeutics, EKB Technology

2005 5Oxford Nanopore Technologies, Oxford RF Sensors, Oxbridge Pulsars, Celleron, Oxford Catalysts*

2006 7TDeltaS, Oxford Medistress, Particle Therapeutic, Aurox, Oxford Advanced Surfaces*, Cytox, OxTox

2007 4 Eykona Technologies, Clinox, Oxford Biodynamics, Crysalin

2008 4 Semmle, Oxford-Emergent TB Consortium, Navetas(ISE), Organox

2009 3 Oxford Financial Computing, Zyoxel, Oxford Yasa Motors

2010 4 OxEms, Kepler Energy, IXO, Oxford PhotoVoltaic

2011 5 Oxyntix, Oxtex, Oxford Multi Spectral, Oxford Imaging Detectors, OCB

2012 4 Intelligent Ultrasound, OxEHealth, Oxford Vacmedix, Run3D

2013 [1] Perspectum Diagnostics

Total external investment to date in 66 spin-outs since 2000: £340m £46m 1st round Seed/Business Angels – £294m follow-on Investment Capital

Oxford BioCluster

Oxford Science Park

Harwell

Proposed Oxford BioEscalator • Translate science into business • Launch pad for sustainable

new companies • Centre for industrial

collaboration • Located on university /

hospital site • Advice and support as well as

facilities • Drug Discovery, MedTech,

Diagnostics, TeleHealth, Data Analyses ++

The Centre for the Advancement of Sustainable Medical innovation

http://casmi.org.uk

Universities in the Oxford AHSN University Key areas

University of Oxford Medical Sciences Division: Said BS, Engineering: Computing

University of Reading Faculty of Life Sciences (including Nutrition and Pharmacy): Knowledge Transfer Centre: Henley BS

Buckinghamshire New University Nursing: clinical innovations: healthcare professions

Oxford Brookes University Faculty of Health and Life Sciences: Nutrition: Computing: Social Work: Business School

Open University Remote learning: Biomedical Sciences: IT: Innovations

University of Bedfordshire Nursing and healthcare professions

University of Buckingham Clinical MD in internal medicine

University of West London Nursing and Healthcare Professions

University of Cranfield Healthcare Faculty: Aerospace

Larger Businesses in Oxford Region

Agenda • The Opportunity for UK Life Sciences

• AHSN Concept

• Oxford Region

• Oxford AHSN

Oxford Region : Doing well but can do even better

• Consistently deliver best care • Commercialise more university / NHS science • Create, attract and nurture stronger start ups • More industrial collaboration • Longer term industrial partnerships • Lead medical knowledge management • Lead new approaches and technologies – “Open

Innovation”, “Big Data”, “Genomics” etc. • Connect and energise the region • Build a stronger global network • Be the best at collaboration and cooperation

Oxford Academic Health Science Network

Clinical Networks • Quantify current local health status • Set tough targets for health improvement • Develop strategies to improve health • Work with researchers and the NIHR to

support research • Evaluate promising health innovations

and technologies • Set priorities • Support innovation implementation

to…..

Improve Patient Care for Specific Conditions

Exemplar Innovations

• MapMyDiabetes - Jonathan Rachman • Blood Transfusion System - Mike Murphy • Intelligent Ultrasound - Alison Noble • OxTex - David Jackson • OxeHealth - Lionel Tarrasenko • Islet Cell Transplantation - Stephen Gough

The AHSN will support NHS adoption and dissemination

Conclusions on Partnering

• Industry, NHS and Universities need to work together to create major medical innovations

• Collaboration must bring clear benefits to all • Partnering is not easy and can benefit from a

“third party” • The AHSN initiative gives us a chance to create

world leading cooperation and collaboration

Questions, Comments and Discussion

Please visit us at www.OxfordAHSN.org

How can the Oxford AHSN best support our Medical Innovation ecosystem ?